US6878206B2
(en)
|
2001-07-16 |
2005-04-12 |
Applied Materials, Inc. |
Lid assembly for a processing system to facilitate sequential deposition techniques
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
JP4886511B2
(ja)
|
2003-07-30 |
2012-02-29 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
2,4−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
|
ES2578254T3
(es)
*
|
2003-12-03 |
2016-07-22 |
Ym Biosciences Australia Pty Ltd |
Inhibidores de cinasas basados en azol
|
AU2005252160A1
(en)
|
2004-04-13 |
2005-12-22 |
Astellas Pharma Inc. |
Polycyclic pyrazines as potassium ion channel modulators
|
US7884109B2
(en)
*
|
2005-04-05 |
2011-02-08 |
Wyeth Llc |
Purine and imidazopyridine derivatives for immunosuppression
|
KR101312225B1
(ko)
|
2005-06-08 |
2013-09-26 |
리겔 파마슈티칼스, 인크. |
Jak 경로의 억제를 위한 조성물 및 방법
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
ES2351357T3
(es)
*
|
2005-07-26 |
2011-02-03 |
Vertex Pharmaceuticals Incorporated |
Bencimidazoles útiles como inhibidores de proteínas cinasas.
|
LT2848258T
(lt)
|
2005-10-26 |
2018-02-26 |
Novartis Ag |
Šeiminės viduržemio jūros karštligės gydymas su anti-il-1 beta antikūnais
|
US9006224B2
(en)
|
2005-11-21 |
2015-04-14 |
Novartis Ag |
Neuroendocrine tumor treatment
|
GB0601744D0
(en)
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
US7989459B2
(en)
*
|
2006-02-17 |
2011-08-02 |
Pharmacopeia, Llc |
Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
|
EP1991532B1
(en)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2007109362A2
(en)
|
2006-03-20 |
2007-09-27 |
Synta Pharmaceuticals Corp. |
Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
|
WO2007112093A2
(en)
*
|
2006-03-23 |
2007-10-04 |
Synta Pharmaceuticals Corp. |
Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
AR063142A1
(es)
|
2006-10-04 |
2008-12-30 |
Pharmacopeia Inc |
Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
|
WO2008043019A1
(en)
*
|
2006-10-04 |
2008-04-10 |
Pharmacopeia, Inc |
8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
|
CA2673125C
(en)
|
2006-10-19 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
AU2013273769B2
(en)
*
|
2006-11-15 |
2016-05-12 |
Ym Biosciences Australia Pty Ltd |
Inhibitors of Kinase Activity
|
US8461161B2
(en)
*
|
2006-11-15 |
2013-06-11 |
Ym Biosciences Australia Pty Ltd |
Substituted pyrazines as inhibitors of kinase activity
|
US20080119496A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Pharmacopeia Drug Discovery, Inc. |
7-Substituted Purine Derivatives for Immunosuppression
|
KR20100014271A
(ko)
*
|
2006-11-16 |
2010-02-10 |
파마코페이아, 엘엘씨. |
면역 억제를 위한 7-치환된 퓨린 유도체
|
EP3406263A1
(en)
|
2007-05-29 |
2018-11-28 |
Novartis AG |
New indications for anti-il-1beta therapy
|
CL2008001933A1
(es)
|
2007-06-29 |
2009-09-25 |
Millennium Pharm Inc |
Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
|
US7968536B2
(en)
|
2007-06-29 |
2011-06-28 |
Millennium Pharmaceuticals, Inc. |
Heterocyclic compounds useful as RAF kinase inhibitors
|
US8415358B2
(en)
|
2007-09-17 |
2013-04-09 |
Neurosearch A/S |
Pyrazine derivatives and their use as potassium channel modulators
|
EP2214486A4
(en)
|
2007-10-19 |
2011-03-09 |
Avila Therapeutics Inc |
HETEROARYL COMPOUNDS AND ITS USES
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
EP2209916B1
(en)
|
2007-11-08 |
2011-12-21 |
Novartis AG |
Gene expression signatures for chronic/sclerosing allograft nephropathy
|
RU2010129928A
(ru)
*
|
2007-12-19 |
2012-01-27 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Пиразоло[1, 5-а]пиримидины, используемые в качестве ингибиторов jak2
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
PT2323993E
(pt)
|
2008-04-16 |
2015-10-12 |
Portola Pharm Inc |
2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
|
CN102066339B
(zh)
|
2008-04-16 |
2014-09-24 |
波托拉医药品公司 |
作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
CA2723185A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
CA2723358A1
(en)
*
|
2008-05-05 |
2009-11-12 |
Allison B. Reiss |
Method for improving cardiovascular risk profile of cox inhibitors
|
US20100035875A1
(en)
|
2008-06-20 |
2010-02-11 |
Bing-Yan Zhu |
Triazolopyridine jak inhibitor compounds and methods
|
CN102131389A
(zh)
|
2008-06-20 |
2011-07-20 |
健泰科生物技术公司 |
***并吡啶jak抑制剂化合物和方法
|
KR101892989B1
(ko)
|
2008-06-27 |
2018-08-30 |
셀젠 카르 엘엘씨 |
헤테로아릴 화합물 및 이의 용도
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
CA2767616A1
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
CA2797772A1
(en)
*
|
2010-04-30 |
2011-11-03 |
Cellzome Limited |
Pyrazole compounds as jak inhibitors
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
JP6068340B2
(ja)
|
2010-08-10 |
2017-01-25 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
Btk阻害剤のベシル酸塩
|
JP5956999B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
EP2635284B1
(en)
|
2010-11-01 |
2019-12-18 |
Celgene CAR LLC |
Heterocyclic compounds and uses thereof
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
JP2014501705A
(ja)
|
2010-11-01 |
2014-01-23 |
ポートラ ファーマシューティカルズ, インコーポレイテッド |
Syk調節剤としてのベンズアミドおよびニコチンアミド
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
変異体選択的egfr阻害剤およびその使用
|
US8889684B2
(en)
*
|
2011-02-02 |
2014-11-18 |
Boehringer Ingelheim International Gmbh |
Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(α-經取代之芳烷胺基及雜芳烷胺基)嘧啶基及1,3,5-三基苯并咪唑,其醫藥組合物及其在治療增生性疾病之用途
|
EP2710006A1
(en)
|
2011-05-17 |
2014-03-26 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
CN102267980B
(zh)
*
|
2011-06-04 |
2012-11-21 |
山西大学 |
2,6-二苯并咪唑基吡啶的制备方法
|
CN103608349A
(zh)
|
2011-06-27 |
2014-02-26 |
诺瓦提斯公司 |
四氢-吡啶并-嘧啶衍生物的固体形式和盐
|
EP2729466B1
(en)
|
2011-07-08 |
2015-08-19 |
Novartis AG |
Novel pyrrolo pyrimidine derivatives
|
JP2014530851A
(ja)
|
2011-10-21 |
2014-11-20 |
ノバルティスアーゲー |
Pi3kモジュレータとしてのキナゾリン誘導体
|
TW201325593A
(zh)
|
2011-10-28 |
2013-07-01 |
Celgene Avilomics Res Inc |
治療布魯頓(bruton’s)酪胺酸激酶疾病或病症之方法
|
IN2014CN04065A
(ja)
|
2011-11-23 |
2015-09-04 |
Portola Pharm Inc |
|
US20140348848A1
(en)
|
2011-12-02 |
2014-11-27 |
Dhananjay Kaul |
Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
EA029473B1
(ru)
|
2011-12-15 |
2018-03-30 |
Новартис Аг |
Применение ингибиторов pi3k для лечения острой и церебральной малярии
|
KR101656592B1
(ko)
|
2011-12-22 |
2016-09-23 |
노파르티스 아게 |
디히드로-벤조-옥사진 및 디히드로-피리도-옥사진 유도체
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
CA2861010A1
(en)
|
2012-01-13 |
2013-07-18 |
Xiao Xu |
Heterocyclic compounds and uses as anticancer agents
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
KR102081042B1
(ko)
|
2012-03-15 |
2020-02-26 |
셀젠 카르 엘엘씨 |
상피 성장 인자 수용체 키나제 억제제의 고체 형태
|
CA2866857C
(en)
|
2012-03-15 |
2021-03-09 |
Celgene Avilomics Research, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
MX2015001081A
(es)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
|
US9573958B2
(en)
|
2012-08-31 |
2017-02-21 |
Principia Biopharma, Inc. |
Benzimidazole derivatives as ITK inhibitors
|
EP2903970A4
(en)
|
2012-10-08 |
2016-11-30 |
Portola Pharm Inc |
SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
|
SG10201600149VA
(en)
|
2012-11-21 |
2016-02-26 |
Ptc Therapeutics Inc |
Substituted reverse pyrimidine bmi-1 inhibitors
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
EP2935226A4
(en)
|
2012-12-21 |
2016-11-02 |
Celgene Avilomics Res Inc |
HETEROARYL COMPOUNDS AND USES THEREOF
|
EP3007689B1
(en)
|
2013-01-10 |
2018-03-07 |
Pulmokine, Inc. |
Non-selective kinase inhibitors
|
CA2897279C
(en)
|
2013-01-23 |
2020-12-29 |
Astrazeneca Ab |
Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer
|
TW201446745A
(zh)
|
2013-02-08 |
2014-12-16 |
Celgene Avilomics Res Inc |
Erk抑制劑及其用途
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
WO2015006754A2
(en)
|
2013-07-11 |
2015-01-15 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
EP3039015B1
(en)
|
2013-08-30 |
2019-10-30 |
PTC Therapeutics, Inc. |
Substituted pyrimidine bmi-1 inhibitors
|
JP6494634B2
(ja)
|
2013-09-22 |
2019-04-03 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
置換されているアミノピリミジン化合物および使用方法
|
ES2959419T3
(es)
|
2013-10-11 |
2024-02-26 |
Pulmokine Inc |
Formulaciones secas por aspersión
|
WO2015076800A1
(en)
*
|
2013-11-21 |
2015-05-28 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine bmi-1 inhibitors
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
US10112926B2
(en)
|
2014-04-24 |
2018-10-30 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
EP3134395B1
(en)
|
2014-04-24 |
2018-01-31 |
Novartis AG |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
AU2014391608A1
(en)
|
2014-04-24 |
2016-10-27 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
EP3825417A3
(en)
|
2014-05-22 |
2021-09-15 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
TWI679205B
(zh)
|
2014-09-02 |
2019-12-11 |
日商日本新藥股份有限公司 |
吡唑并噻唑化合物及醫藥
|
GB201518456D0
(en)
*
|
2015-10-19 |
2015-12-02 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
|
TWI712604B
(zh)
|
2016-03-01 |
2020-12-11 |
日商日本新藥股份有限公司 |
具jak抑制作用之化合物之結晶
|
KR20230109185A
(ko)
|
2016-06-07 |
2023-07-19 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
CN110087653A
(zh)
|
2016-10-27 |
2019-08-02 |
普尔莫凯恩股份有限公司 |
用于治疗肺高血压的组合疗法
|
TWI664175B
(zh)
|
2017-03-23 |
2019-07-01 |
大陸商北京加科思新藥研發有限公司 |
用於作為shp2抑制劑之新穎雜環衍生物
|
JP2020516682A
(ja)
|
2017-04-07 |
2020-06-11 |
エイシア セラピューティクス, インコーポレイテッド |
ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
|
EP3630118A4
(en)
|
2017-05-23 |
2021-03-31 |
MEI Pharma, Inc. |
POLYTHERAPY
|
MA49921A
(fr)
|
2017-08-14 |
2021-05-12 |
Mei Pharma Inc |
Polythérapie
|
WO2019079369A1
(en)
|
2017-10-19 |
2019-04-25 |
Effector Therapeutics, Inc. |
BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2
|
KR20200090154A
(ko)
|
2017-10-27 |
2020-07-28 |
상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 |
알파 단백질 키나제 1의 활성화에 의해 면역 반응을 조절하는 조성물 및 방법
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
US20220202820A1
(en)
|
2019-04-16 |
2022-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
MX2021014157A
(es)
|
2019-05-23 |
2022-01-04 |
Novartis Ag |
Formas cristalinas de un inhibidor btk.
|
CN112358468B
(zh)
*
|
2020-11-10 |
2022-03-22 |
德州德药制药有限公司 |
一种工业化合成azd9291的方法
|
CN112980809B
(zh)
*
|
2021-03-17 |
2023-04-11 |
云南中烟工业有限责任公司 |
一种烟草法尼基焦磷酸合酶基因及其应用
|
WO2023083330A1
(zh)
*
|
2021-11-12 |
2023-05-19 |
百极优棠(广东)医药科技有限公司 |
Drak2抑制剂及其制备方法和应用
|
WO2023222565A1
(en)
|
2022-05-16 |
2023-11-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|